Purpose of review The purpose of this review is to discuss whether vascular dysfunction and autonomic dysfunction are related to primary open-angle glaucoma stratified by the intraocular pressure (IOP) level.
INTRODUCTION
In primary open angle glaucoma (POAG), there are no obvious anterior segment abnormalities and the filtration angle is physically open, whereas the optic head is excavated and the neuroretinal rim is eroded. There are no obvious clinical clues regarding why the intraocular pressure (IOP) is elevated in the POAG subset referred to as high-tension glaucoma (HTG) cases. Furthermore, it is unclear why optic nerve degeneration develops in patients in the POAG subset referred to as normal-tension glaucoma (NTG) cases. The ultimate goal in POAG is to define the disease in terms of biochemical pathways as opposed to describing it as an IOP-related optic neuropathy without obvious secondary cause. It is likely that the term POAG encompasses several diseases produced by distinct biochemical mechanisms. On an interim basis, it is reasonable to stratify POAG into HTG and NTG subtypes and ask if candidate disease mechanisms are operative at higher or lower IOP at presentation. In fact, from an experimental perspective, it makes sense to compare NTG patients with controls with similar IOP to explore whether any putative mechanism makes the optic nerve vulnerable to degeneration in POAG. Here, we will discuss whether two pathophysiologic processes -vascular dysfunction and autonomic dysfunction -are related to POAG stratified by the IOP level associated with optic nerve degeneration.
TEXT OF REVIEW

Vascular dysfunction in primary open-angle glaucoma
Broadly speaking, the endothelial monolayer functions at the interface between the blood and underlying interstitial tissue to modulate vascular tone, thrombus formation, cell adhesion, smooth muscle proliferation, and directed sequestration of inflammatory mediators. One hypothesis is that POAG is categorized by impaired chemical endothelial signaling between both: the inner wall Schlemm's canal endothelial cells as well as endothelial cells located in the ciliary body and the posterior longitudinal muscle that helps to set outflow resistance, and the ocular vascular endothelial cell and underlying luminal smooth muscle for vessels supplying the retinal ganglion cells (RGCs). This hypothesis could explain why POAG occurs across a spectrum of IOP but it does not consider the role that systemic endothelial cell dysfunction may play in the disease.
What is the evidence for endothelial cell dysfunction in POAG and what are biological mediators of this impairment? A pharmacologic intervention study in untreated NTG patients found that forearm blood vessels demonstrated impaired vasodilation in response to intravenous acetylcholine [1] . This finding suggests there is a generalized abnormality of vascular endothelium in POAG. Various researchers have studied flow-mediated vasodilation in the brachial artery and found that both NTG and HTG patients had impaired responses compared with controls [2] [3] [4] . One group provided evidence that impaired flow-mediated vasodilation was related to reduced circulating endothelial progenitor cells, which are derived from the bone marrow and serve to replace and repair the endothelial cell lining [3] . Evans et al. [5] compared the changes in retrobulbar ocular blood flow in POAG patients with normal study participants during supine and upright posture. They concluded that posture change exposes a vascular autoregulatory abnormality in the vessels distal to the central retinal artery. Feke et al. [6, 7] confirmed these results in HTG and NTG cases. In open-angle glaucoma (OAG), there is evidence for vascular dysregulation in the choroids [8, 9] , optic nerve head [10, 11] , central retinal artery [12] , and perifoveal macular capillaries [13] . In fact, there is evidence that this vascular dysregulation extends to the cerebral vasculature [14] .
As compromised endothelial cell signaling plays a role in POAG, it is important to discover the biological mediators of this impairment. This information could translate into more rational treatments for POAG. There is compelling evidence that impaired nitric oxide (NO) signaling plays an important role in the endothelial cell dysfunction associated with POAG and this evidence comes from human genetics and laboratory studies. One study found no difference in two functional nitric oxide synthase 3 (NOS3) gene variants (the gene coding for the enzyme responsible for NO generated by vascular endothelium) between HTG and NTG cases [15] . Conversely, several other research groups [16] [17] [18] [19] [20] [21] [22] [23] have found associations between functional NOS3 gene variants and POAG cases versus controls. In fact, three studies found that the À786C/T NOS3 locus is associated with HTG, particularly in women (Table 1) [16, 22, 23] . Interestingly, the À786C/T NOS3 polymorphism is a function variant that results in reduced NO levels in cells because of alterations in NOS3 transcription rates [24] . In addition, polymorphisms in the genomic region corresponding to the caveolin genes, which code for proteins that reciprocally control NOS3 activity in endothelial endocytotic membranes [25] , are also associated with POAG [26 & ]. The association between caveolin (CAV) variants and POAG was particularly strong for early paracentral vision loss cases. Although one study found that the maximum untreated IOP in early paracentral visual field loss cases (21.6 mmHg) was lower than in isolated peripheral visual loss cases (28.3 mmHg), the IOP in the paracentral cases was still above the statistical norm [27] . Another study did not find more paracentral visual loss in NTG versus HTG, suggesting there is a range of IOP at presentation for this pattern of glaucomatous damage [28] . When soluble guanylate cyclase (sGC), the intracellular receptor for NO, is knocked out in a murine model, IOP increases nominally ($1-2 mmHg), there is abnormal retinal vascular reactivity to NO donators, and optic nerve degeneration ensues [29 && ]. Interestingly, a polymorphism (rs11722059) in the genomic region between GUCY1A3 (codes for the alpha-1 subunit of soluble guanylate cyclase) and GUCY1B3 (codes
KEY POINTS
Impaired nitric oxide signaling, altered endothelin generation after physiologic perturbation and reduced circulating endothelial progenitor cells all appear to be aspects of a systemic endothelial cell dysfunction in primary open-angle glaucoma (POAG).
Vascular beds throughout the body exhibit abnormalities in POAG patients.
Beat-to-beat variability in heart rate represents a form of autonomic dysfunction documented in POAG patients who present with a variety of intraocular pressures.
for the beta 1 subunit of soluble guanylate cyclase) was associated with POAG among women with early paracentral visual loss [29 && ]. This locus is in high linkage disequilibrium with another GUCY1A3/ GUCY1B3 variant (rs13139571) associated with blood pressure in a large European consortium [30] . These data suggest a biochemical pathway starting with endothelial cell acetylcholine receptor activation and concluding with smooth muscle cell relaxation plays an important role in POAG pathogenesis ( Fig. 1) .
Endothelin-1 (ET-1), a 21 amino acid peptide made by vascular endothelium throughout the body, including tissues relevant to glaucoma (nonpigmented ciliary epithelium, ciliary body muscle, and iris [31] ), is a potent vasoconstrictor and serves to counterbalance endothelial cell NO-mediated vasodilation. Considerable interest in ET-1 emerged when perineural optic nerve delivery in rabbits produced optic nerve excavation without elevated IOP [32] . However, ET-1 is not an NTG-specific biomarker as subsequent studies found that plasma ET-1 levels were not necessarily higher in NTG compared with HTG or chronic angle closure glaucoma [33] [34] [35] . In fact, not every study shows that ET-1 levels are higher in glaucoma subtypes versus controls [34, 35] . ET-1 is abluminally directed from the endothelial cell to the underlying smooth muscle, and assessing serum levels may not be sufficiently sensitive to understand the role this peptide plays in glaucoma pathogenesis. Nonetheless, interventional studies with NTG patients clearly implicate the endothelin processing system in glaucoma pathogenesis. For example, the physiological increase in ET-1 plasma levels after shifting from supine to standing was absent in NTG patients [34] . After cold-pressor challenge associated with donning a cooling head vestment for 30 min, POAG patients experienced a 34% increase in plasma ET-1 levels compared with only a 7% increase in controls [36] . Patients with progressive POAG had higher ET-1 levels compared with those with stable disease [37] . Interestingly, although untreated NTG patients had a normal systemic vasoconstriction when exposed to intra-arterial ET-1, intra-arterial injection of a selective endothelin A (ET A ) receptor antagonist (BQ123) produced less forearm vasodilation than in controls [38] . This is a critical experiment because there are two endothelin receptors -ET A and ET B -and antagonism of ET A unmasks ET B -related activation of the NO-sGC pathway that produces vasodilation. Therefore, antagonizing ET A could expose an impaired NOmediated response via ET B activation, although other explanations must also be considered such as increased ET B -receptor-mediated vascular tone or preexisting poor ET A -receptor-mediated tone. The cardiology literature indicates that ET A -receptor antagonist-mediated vasodilation is inhibited by blocking NO synthesis [39] . Overall interaction with ET A and ET B receptors is intertwined with NO production, which is key for physiologically appropriate vascular regulation. It is clear that endothelin processing is abnormal in POAG, especially in NTG patients, but the problem is complex and may point more to NO than to endothelin itself. To complicate matters further the problem with NO may involve how NOS3 interacts with caveolin as retinal blood flow tends to respond passively to posture change in POAG [6, 7] . Available studies show no significant relation between various endothelin processing gene variants (see Fig. 2 for the genes involved in ET-1 processing) and POAG after controlling for multiple comparisons [40,41,42 & ], although more study is needed. This is in contrast to the evidence of replication for associations between a functional variant in the NOS3 promoter region (À786C), which is adversely associated with HTG in women [16, 22, 23] , and between CAV1/CAV2 variants and POAG [43, 44] .
How do we reconcile the impaired NO signaling paradigm in POAG with the observed increased disc hemorrhages, which represents an important biomarker of glaucoma progression? First, we must revisit optic nerve anatomic features that would make it vulnerable to damage in the face of vascular dysregulation. It is important to remember that central retinal artery occlusion produces selective RGC layer dropout, a feature shared with glaucoma. Furthermore, a subset of POAG patients with paracentral loss will develop fairly profound loss of retinal sensitivity in a discrete visual field zone resembling vascular injury. The optic nerve can be considered a neurovascular pedicle, where vessels make acute turns as they emerge onto the retinal surface. This creates opportunity for large shear forces to develop in the smaller vessels if there are significant alterations in blood flow. If shear forces exceed the loading capacity of the vessel wall, then the vessel will rupture and bleed. Second, the scleral ring of Elschnig serves to create a compartment syndrome in the prelaminar portion of the optic nerve head. Thus optic nerve hemorrhages can act like space occupying lesions and compress RGC axons in the optic nerve head. Simple positional changes such as laying down prompt physiologic increases in ocular perfusion pressure (blood pressure minus IOP) of $30 mmHg [6] . Such hemodynamic changes must be accompanied by changes in vascular tone that keep ocular blood flow relatively constant. Studies of retinal blood flow changes unmasked by positional change suggest that in POAG these vessels behave like passive sieves, with blood flow increasing as much as 100% when patients recline for 30 min [45] . It is suspected that some complex interaction between ET-1, NO and CAV1 is responsible for this aberrant retinal hemodynamic response to posture change. Such increases in retinal blood flow could translate into large shear forces that induce hemorrhaging in lamina cribrosa capillaries. In the Ocular Hypertension Treatment Study [46] , the Normal Tension Glaucoma Study [47] , and the Early Manifest Glaucoma Treatment Study [48] , disc hemorrhage was associated with disease progression in multivariable models that also account for IOP. Nonetheless, disc hemorrhage does occur in chronic angle closure glaucoma, suggesting that it could also be a secondary event after IOP-induced optic nerve damage [49] . The reason why disc hemorrhages might occur more commonly in NTG than HTG may relate to the fact that the higher IOP tamponades the microbleeding that occurs in HTG cases.
If disc hemorrhages in POAG reflect the workings of an impaired NO signaling system, then interventions that improve NO signaling could stop disc hemorrhages and stabilize visual field loss. Interestingly, the Low Pressure Glaucoma Treatment Study [50] found that brimonidine, an a2 agonist that has vasomodulatory activity mediated through NO signaling [51] , was effective in slowing visual field loss in NTG patients. Brimonidine use was also associated with a trend toward less frequent occurrence of disc hemorrhages [52 && ]. The counter view that the study did not demonstrate the neuroprotective effect of brimonidine but rather the deleterious effect of timolol seems unlikely. First, the disease progression in the timolol arm of the study (39% in 3 years) was comparable with the untreated arm of the Collaborative NTG Study (35%) [53] . Second, in the Early Manifest Glaucoma Treatment Study, patients with OAG across the spectrum of IOP-achieved neuroprotective benefited from treatment consisting of laser trabeculoplasty plus betaxolol versus observation [54] .
Autonomic dysfunction in primary open-angle glaucoma
The autonomic nervous system (ANS) is housed in the medulla oblongata with the hypothalamus serving as an integrator. The ANS has parasympathetic, sympathetic, and enteric arms that controls many bodily functions, including body temperature, heart rate, breathing rate, perspiration, digestion, salivation, swallowing, coughing, sneezing, vomiting, sexual arousal and function, pupil diameter, and accommodation. Interestingly, the parasympathetic and sympathetic arms of the ANS are therapeutic targets for glaucoma. The level of IOP may itself be partially controlled by the ANS. In fact, chemical stimulation of the dorsomedial and perifornical hypothalamus where central autonomic regulatory neurons are housed, causes marked rises in IOP [55] . This is interesting because diurnal variation in IOP is more variable in POAG patients compared with controls [56] . This wider fluctuation in IOP coupled with instability of blood flow regulation probably contributes to POAG, regardless of IOP level. It should be noted that the ability to regulate retinal blood flow is only partially under autonomic function as there is a paracrine control of blood flow in the retina, where vessels are not innervated [57] .
Patients with familial dysautonomia who exhibit a wide array of autonomic function abnormalities uniformly exhibit an optic nerve phenotype. The optic nerve disorder seen in familial dysautonomia predominately involves the maculopapillary bundles, pathologic features shared by some POAG patients (as discussed above), and by patients with mitochondrial disease [58, 59 && ]. Another disease with well known vasomotor and autonomic abnormalities is nail-patella syndrome [60] , a condition that represents a familial form of NTG [61] caused by LMX1B (which codes for LIM homeobox transcription factor-1 beta) [62] . Interestingly, common variants in LMX1B are linked to both NTG and HTG [63] . At this juncture, the link between LMX1B and autonomic dysfunction is not entirely clear. What is quite remarkable is that three studies showed reduced low-frequency heart rate variability in NTG patients versus controls, and these changes are not accompanied by dramatically different blood pressure, even during the nocturnal period [64] [65] [66] [67] . However, other studies suggest features consistent with cardiac autonomic dysfunction are shared by HTG [68, 69] and exfoliation glaucoma patients [70] . The problem of autonomic dysfunction seems inextricably linked to endothelial cell dysfunction in that affected NTG patients with low-frequency heart rate variability tend to have paracentral visual defects and concomitant nail fold microvascular abnormalities [71] . Furthermore, these patients also tend to have higher plasma ET-1 than age matched controls [72] . Aside from cardiovascular autonomic function, other bodily functions under the ANS have not been well studied in NTG, or HTG and this represents a research opportunity in the field glaucoma.
CONCLUSION
Although one cannot claim that impaired NO and endothelin signaling represents a unifying hypothesis in our understanding of POAG, they do appear to play an important role in disease pathogenesis for both HTG and NTG cases. This discussion highlights the role of genetics in contributing to this process. It appears that subendothelial plaque formation (atherosclerosis with endothelial cell proliferation) is not an aspect of endothelial dysfunction in POAG [73] . Furthermore, POAG patients do not have increased risk of cardiovascular-related mortality [74] . Although studies focused on NTG patients have helped to highlight mechanisms involved in optic nerve degeneration in POAG, these mechanisms are operative in NTG and HTG. More studies with novel alternative stratification of POAG (such stratifying disease on the basis of visual field loss patterns) are needed. The current body of knowledge reviewed here clearly implicates systemic processes in POAG, and these processes need to be addressed if we are going to more favorably impact this disease. More study in the fields of genetic epidemiology, immunology, and cardiovascular medicine are likely to contribute to an improved understanding of POAG. Hopefully, we may someday drop the word 'primary' from POAG and replace it with real descriptors that speak to the multiple causes that exist in this condition.
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